GLP-1 Drugs Linked to Fewer Hip Replacement Revisions Than Surgery

Hip-replacement patients who were taking a GLP-1 receptor agonist beforehand had less than half the 90-day revision rate of patients who'd had bariatric surgery to lose weight before the same operation, according to a retrospective study published October 7 in the HSS Journal, the peer-reviewed journal of New York's Hospital for Special Surgery.

What the study found

Researchers led by Shaan Brahmbhatt pulled records from TriNetX, a federated network of electronic health records, covering adults who had a primary total hip arthroplasty between 2015 and 2025. They compared two groups who had tried to lose weight before surgery by different routes: 6,877 patients with an active prescription for a GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, albiglutide or lixisenatide) in the 18 months before their operation, and 3,960 patients who'd had bariatric surgery — gastric bypass, sleeve gastrectomy, banding or biliopancreatic diversion — in the same window. After matching patients 1:1 on demographics and health history, 2,640 pairs remained.

In the first 90 days after surgery, the GLP-1 group had lower odds of nearly every complication the authors tracked: revision surgery (0.7% vs. 1.8%, odds ratio 0.40), periprosthetic joint infection (1.3% vs. 2.9%, OR 0.43), hospital readmission (0.7% vs. 2.1%, OR 0.32), ED visits (8.5% vs. 13.1%, OR 0.62), wound dehiscence, joint dislocation and the need for surgical debridement. All of those differences were statistically significant. Rates of periprosthetic fracture and surgical-site infection were not significantly different between the groups. The gap narrowed but didn't close by one year: revision risk was still 47% lower and readmission 56% lower in the GLP-1 group.

Why the comparison, and not the obvious causes

The authors frame this as a comparison between two routes to the same end — weight loss before a joint replacement — not a test of GLP-1 drugs against doing nothing. Both interventions are meant to reduce the surgical risk that comes with higher body weight. Bariatric surgery changes gut anatomy and absorption; it can also leave patients with lower protein and micronutrient levels going into a major operation, which plausibly affects wound healing and infection resistance. GLP-1 receptor agonists slow gastric emptying and reduce appetite without cutting or rerouting anything, which the authors suggest may explain some of the gap, though the study wasn't designed to test that mechanism directly. Readers unfamiliar with how a GLP-1 agonist works can find a plain-language explainer at Torrey Labs' compound guide.

What's known, and what's still thin

This single study, however large its database, sits inside a thinner and more mixed evidence base than the topline numbers suggest. A systematic review and meta-analysis in Cureus published last November pooled six earlier U.S. retrospective cohorts — 11,869 GLP-1 users against 22,777 controls who had no weight-loss intervention at all before hip replacement — and found a narrower, shakier picture: 90-day readmission and short-term revision were modestly lower (odds ratios of 0.81 and 0.70), but infection rates, blood clots and wound complications showed no statistically significant difference either way. The review rated the certainty of evidence "very low" for most outcomes, using the GRADE framework, and the authors called their own findings exploratory. A broader pooled analysis published by the evidence-synthesis group OrthoEvidence in 2026, covering 12 studies and over 100,000 patients, reached a similar split verdict: lower infection and readmission rates after GLP-1 use, but a higher rate of periprosthetic fracture at one year, especially after knee replacement.

None of these studies is a randomized trial, and the new HSS Journal paper is explicit about why that matters: patients who end up on a GLP-1 prescription and patients who end up on an operating table for bariatric surgery are not interchangeable to begin with. People who choose or qualify for weight-loss surgery often have higher starting BMI, more severe comorbidities, or exhausted other options first; people on a GLP-1 drug may simply be earlier in that process. The TriNetX database also doesn't record which specific drug, dose or duration a patient was on, so the label GLP-1 use here is really a stand-in for a wide range of regimens and starting points. The authors matched on 1-year, not longer, follow-up, which captures early surgical risk but says nothing about how the implants hold up over a decade — or whether the fracture signal seen in the larger pooled analysis would show up here too, given more time.

The backdrop to all of it: GLP-1 use among hip and knee replacement patients has climbed fast. Hospital for Special Surgery's own internal data, released in April, showed GLP-1 prescriptions among its arthroplasty patients rising from 3.7% in 2021 to nearly 13% in 2024, which is part of why orthopedic surgeons are suddenly generating this much retrospective data on a drug class originally studied for diabetes and weight management rather than surgical outcomes.

What this means for researchers

The honest summary is that GLP-1 use before hip replacement keeps showing up associated with fewer short-term complications across several independent retrospective datasets, which is a real and now-repeated signal, not a fluke. But "associated with" is doing a lot of work in that sentence. Every study so far has compared people who were never randomly assigned to a drug, a surgery, or neither, and the authors of each one say so plainly.

What would move this from a pattern to an answer is the kind of study nobody has run yet: a prospective trial that assigns comparable patients to GLP-1 therapy versus bariatric surgery (or standard care) before a scheduled joint replacement, with pre-specified tracking of septic versus aseptic revisions, implant survival past one year, and the specific agent, dose and duration used. Until then, the periprosthetic-fracture signal in the largest pooled analysis is the kind of loose end that deserves more attention than it's gotten — a dataset built around infection and revision risk can miss a fracture problem showing up on a different timeline. (If nothing else, orthopedics has accidentally generated a decade's worth of natural experiment on a drug nobody designed for this use.)

For a research community already tracking how GLP-1 agonists ripple into fields well outside endocrinology, the honest next step isn't a conclusion — it's a trial design.